Form 4: Climb Bio SVP, Finance & CAO, Emily Pimblett, Reports Stock Transactions

Emily Pimblett, SVP, Finance & CAO of Climb Bio, Inc., reports the conversion of restricted stock units and sale of common stock to cover tax obligations.

Summary

• On March 18, 2025, Emily Pimblett converted 5,000 restricted stock units (RSUs) into 5,000 shares of Climb Bio, Inc. common stock.
• On March 20, 2025, Pimblett sold 1,199 shares of common stock at a weighted average price of $1.31 per share, with prices ranging from $1.31 to $1.325.
• The sale was executed under a pre-arranged 10b5-1 trading plan adopted on April 27, 2024, to cover tax withholding obligations related to the vesting of RSUs.
• Following these transactions, Pimblett directly owns 15,130 shares of Climb Bio, Inc. common stock and 20,000 restricted stock units.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock transactions by an officer, which are part of a pre-arranged plan to cover tax obligations.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings to gauge management's sentiment and confidence in the company's prospects.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders, as mandated by the SEC.
• The use of 10b5-1 trading plans is a common strategy for corporate insiders to sell shares while avoiding accusations of trading on non-public information; many companies such as Tesla, Apple, and Microsoft have executives who utilize these plans.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the small volume of shares sold.

Key Dates

Keywords

Form 4, insider trading, stock sale, restricted stock units, CLYM, Climb Bio, Inc., Emily Pimblett